Nkarta (NKTX) announced the appointment of Shawn Rose as its next Chief Medical Officer and Head of Research and Development starting on June 23. He replaces David Shook, who will be stepping down from the role to pursue other opportunities in the oncology space. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX: